(EMAILWIRE.COM, November 19, 2000 ) (Newstream) -- Trizivir(r), a new product that combines three anti-HIV medicines into one single tablet, has been approved by the Food and Drug Administration (FDA). This marks an important advance for dosing of combination drug regimens. Patients for whom Trizivir is prescribed will now be able to take this three-drug HIV medicine as one tablet twice a day.

Trizivir(R) Tablets combine the two widely used HIV medications Epivir(R) (lamivudine), also known as 3TC, and Retrovir(R) (zidovudine; AZT), along with Ziagen(R) (abacavir sulfate), and is the first product to combine three antiretroviral drugs into a single tablet. (Epivir and Retrovir are already available in a dual combination product, Combivir(R) (lamivudine/zidovudine)). Trizivir can be taken as one tablet in the morning and one tablet in the evening without regard to food or water intake.

Glaxo Wellcome is a pharmaceutical industry leader in HIV research and therapies. Glaxo Wellcome manufactures and markets the widely used anti-HIV medicines Combivir, Epivir, Retrovir, Ziagen and the protease inhibitor Agenerase(R) (amprenavir).

For a full press release, contact Bob Szafranski at 312-558-1770 or via e-mail at bszafranski@pcipr.com.

---------------

Produced for Glaxo Wellcome

Contact:
Bob Szafranski
Public Communications, Inc.
312-558-1770
bszafranski@pcipr.com

---------------

Contact Information:
Glaxo Wellcome
Joseph Nchor
Tel:
Email us


This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.